Storage at -3°C for 24 h alters the immunogenicity of pertussis vaccines

Vaccine

Volumn 19, Issue 25-26, 2001, Pages 3537-3542

  Boros, Christina Ann ^a   Hanlon, M ^b   Gold, M S ^a   Roberton, D M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Immunogenicity; Storage; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; PERTACTIN; PERTUSSIS VACCINE; PLACEBO; TRIPLE ANTIGEN; ACELLULAR VACCINE; ADHESIN; BACTERIUM ANTIBODY; BORDETELLA VIRULENCE FACTOR; FILAMENTOUS HEMAGGLUTININ ADHESIN, BORDETELLA PERTUSSIS; IMMUNOGLOBULIN G; OUTER MEMBRANE PROTEIN; PERTUSSIS TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; DRUG EFFICACY; DRUG STORAGE; ENZYME IMMUNOASSAY; IMMUNOGENICITY; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BORDETELLA PERTUSSIS; CHILD; COMPARATIVE STUDY; FREEZING; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; SPECIES DIFFERENCE;

ADHESINS, BACTERIAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DRUG STORAGE; FREEZING; HEMAGGLUTININS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PERTUSSIS TOXIN; PERTUSSIS VACCINE; SPECIES SPECIFICITY; VACCINES, ACELLULAR; VIRULENCE FACTORS, BORDETELLA;

EID: 0035858824     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00063-9     Document Type: Article

References (43)

1. How common is whooping cough in a non-vaccinating country?
2. Pertussis in Sweden after the cessation of general immunisation in 1987
3. Epidemiology of pertussis in a developed country with low vaccine coverage: The Italian experience
4. Japan's experience in pertussis epidemiology and vaccination in the past thirty years
5. Pertussis Consensus Conference
6. Review of Pertussis in Queensland, 1990-1993
7. Resurgence of Pertussis - United States
8. Annual report of the National Notifiable Disease Surveillance System
9. Pertussis infection among adults during the 1993 outbreak in Chicago
10. Pertussis in adults: Frequency of transmission after household exposure
11. Prevalence and incidence of adult pertussis in an urban population
12. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunised population
13. Pertussis in South Australia 1893 to 1996
14. Expanded programme on immunisation-cold chain evaluation
15. Electronic monitoring of the vaccine cold chain in a metropolitan area
16. The integrity of the vaccine cold chain in the Hunter area of New South Wales
17. How general practitioners store vaccines: A survey in South-Western Sydney
18. Are childhood immunisation programmes in Australia at risk? Investigation of the cold chain in the Northern Territory
19. Cold chain in a hot climate
20. Storage of vaccines in the community: Weak link in the cold chain?
21. Vaccine storage in pediatric offices
22. Special article-office practice. Safe handling of vaccines
23. Expanded programme on immunization. Effects of freezing on the appearance, potency and toxicity of adsorbed and unadsorbed DTP vaccines
24. Effects of freezing in DPT and DPT-IPV vaccines, adsorbed
25. Mouse protection tests in the study of pertussis vaccine: A comparative series using the intracerebral route for challenge
26. Intranasal murine model of Bordetella pertussis infection I. Prediction of protection in human infants by acellular vaccines
27. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells
28. A search for serological correlates of immunity to Bordetella pertussis cough illnesses
29. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis
30. Genetic variation of laboratory outbred Swiss mice
31. Genetic variation within and between strains of outbred Swiss mice
32. Cell-mediated immunity to Bordetella pertussis: Role of TH1 cells in bacterial clearance in a murine respiratory infection model
33. A murine model in which protection correlates with pertussis vaccine efficacy in children demonstrates complementary roles for humoral and cell mediated immunity in protection
34. Randomised controlled trial of two-component, three-component and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine
35. Th1/Th2 dichotomy in acquired immunity to Bordetella pertussis: Variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0
36. A controlled trial of two acellular and one whole-cell vaccine against pertussis
37. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine
38. Comparison of 13 Acellular pertussis vaccines: Overview and serologic response
39. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany
40. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children
41. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants
42. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine in 17-24 month old children, with measurement of 69-kilodalton outer membrane protein antibody